A long-term investor
Wendel is a hands-on investor and shareholder that assists sector-leading companies in their long-term development. Wendel's business model combines the entrepreneurial passion born of a long family tradition with a culture of performance and accountability.
Our companies news
16 March 2010 Stallergenes
2009 Financial Results: Further profit margin growth and significant cash generation
Sales up +13% - Operating profit up 15% - Net profit up 17% - Record free cash flow of €17.5 million (X3.7) - Net cash flow position turned positive - Proposed dividend of 0.55€ (up 22%)
Read more [+]04 March 2010 Bureau Veritas
2009 Full-Year Results: A good performance in a difficult economic backdrop
Revenue of €2,648 million, +4% - Adjusted operating profit of €433 million, +12% - Attributable adjusted net profit of €274 million, +18% - Levered free cash flow of €310 million, +64% - Accelerated de-leveraging, net debt representing less than 1.4x EBITDA at December 31, 2009
Read more [+]01 March 2010 Stahl
Stahl achieves fully consensual restructuring
Stahl, the Netherlands-headquartered speciality chemicals group, has completed its financial restructuring, with unanimous consent from senior, second lien and mezzanine lenders as well as hedge counterparties for its debt-for-equity offering
Read more [+]25 February 2010 Saint-Gobain
2009 Action plan: Ahead of targets - 2009 Dividend unchanged at €1 per share - 2010 Rarget: Strong growth in operating income
Sales prices: +0.8% over the year - Cost savings over the year: €1,100m - Second-half operating income and recurring net income well above the first half: respectively, +38% and +94% - Free cash flow¹ for the year above €1bn (€1,019m), and reduction of €1.4bn in working capital requirements (WCR) - Sharp reduction in capex: -€900m and tight rein on acquisitions, down to €204m - Balance sheet strengthened: €3.1bn of net debt paid down; gearing ratio cut to 53% of equity.
Read more [+]17 February 2010 Legrand
Success for Legrand's first euro bond issue
Legrand today successfully launched and priced its first euro-denominated bond issue, which is for €300 million over seven years. The maturity date is February 24, 2017 and the annual coupon is 4.25%.
Read more [+]11 February 2010 Legrand
2009 full-year results
Margins steady - Net debt reduced by over €500m - High level of investment in innovation
Read more [+]04 February 2010 Bureau Veritas
Bureau Veritas announces 2009 revenue of €2.6 billion and estimates strong growth in adjusted operating profit
Revenue of €2.648 billion: +4% relative to 2008 - Estimated adjusted operating profit of more than €430 million: +12% relative to 2008 - Estimated adjusted operating margin of 16.4%: +120 basis points relative to 2008.
Read more [+]14 January 2010 Stallergenes
Strong sales growth in Q4: up 15% - 2009 sales guidance exceeded: €193 million, up 13%
Sales growth sped up over the fourth quarter to 15%, 3 percentage points higher than that of third quarter 2009. The markets of Northern Europe ("Other EU") and the sublingual route drove this progression but the markets of Southern Europe had an encouraging recovery in growth over the last quarter. Other markets were affected by a negative basis effect due to the strong growth achieved in 2008. Organic growth, after restatement for foreign exchange effects stood at 13% over the quarter and 12% over the full year.
Read more [+]07 December 2009 Stallergenes
Very positive 3-year results of the long-term study provide confirmation of the clinical relevance of Oralair(R)
Stallergenes S.A. today announces the 3-year results of a phase III clinical trial (VO53.06) to assess the long-term (sustained) effect and disease modifier effect after discontinuation of treatment of its sublingual grass pollen immunotherapy tablet, Oralair(R). This study is the first ever pivotal study designed to be a long-term and disease modifier trial from the outset.
Read more [+]27 November 2009 Stallergenes
Stallergenes is granted a marketing authorization for Oralair(R) in Europe
Stallergenes has been granted European approval to market Oralair(R)in both adults and children through a Mutual Recognition Procedure - Germany, the first country where Oralair(R) has been marketed, was the reference Member state.
Read more [+]17 November 2009 Stallergenes
Stallergenes' growth strategy recognized at the BFM Awards
Stallergenes picked up the "best stock market performance" prize at the BFM Awards ceremony held on November 16, 2009. This prize, organized by the French economics-oriented radio station BFM, is awarded to businesses for outstanding corporate performance during the course of the year.
Read more [+]05 November 2009 Legrand
Results for the first nine months of 2009: Full and continuing adaptation to market conditions - Upward revision of 2009 margin target
In the first nine months of 2009, Legrand achieved a maintainable adjusted operating margin of 17.9% despite a 15.7% decline in sales at constant scope of consolidation and exchange rates, and generated a high level of free cash flow - Over the first nine months of the year, production costs plus administrative and sales expense fell by a combined 17.5%at constant scope of consolidation and exchange rates...
Read more [+]04 November 2009 Bureau Veritas
Stable Q3 2009 revenue
Growth in operating margin - Accelerated debt reduction - YTD Q3 2009 revenue totalled €1,968.0 million, up 7.2% relative to YTD Q3 2008 - Q3 2009 revenue totalled €638.5 million, up 0.4% relative to the same period last year...
Read more [+]22 October 2009 Saint-Gobain
Sales for rhe first nine months of 2009
Saint-Gobain's consolidated sales for the first nine months of 2009 came in at 28,435 € million versus E33,435 million for the year-earlier period. This represents a decline of 15.0% on a reported basis and of 14.5% like-for-like (constant Group structure and exchange rates) - Sales for third-quarter 2009: -13.9% on a reported basis and -12.7% like-for-like
Read more [+]15 October 2009 Stallergenes
Continued dynamic growth cumulative sales to the end of September 2009 up 12%
Sales grew at a rate equal to that of the first half year, which was 3 points higher than the growth in the 2nd quarter 2009 - This dynamic remained driven, as in the 1st half year, by the markets of Northern Europe ("Other EU countries") and the sublingual route, which maintained double digit growth rates - This performance must be highlighted against the background of an unfavourable base effect, of strong growth recorded in the 3rd quarter 2008 (+17%).
Read more [+]16 September 2009 Stallergenes
Positive results for a phase IIb/III trial: immunotherapy tablet containing recombinant allergen
Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen and concerning the development of a sublingual immunotherapy tablet containing the recombinant allergen of this pollen, rBet v 1.
Read more [+]27 August 2009 Bureau Veritas
Bureau Veritas announces high growth in H1 2009 earnings
Revenue of E1.3 billion, +11% - Adjusted operating profit of E214.5 million, +19% - Improvement in adjusted operating margin of 110bp - Adjusted attributable net profit of E137.3 million, +22% - Net cash generated from operating activities of E194.1 million, +103%
Read more [+]